Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy.

Nanotechnology-based medical approaches have made tremendous potential for enhancing the treatment efficacy with minimal doses of chemotherapeutic drugs against cancer. In this study, using tamoxifen (Tam), biodegradable antibody conjugated polymeric nanoparticles (NPs) was developed to achieve targeted delivery as well as sustained release of the drug against breast cancer cells. Poly(D,L-lactic-co-glycolic acid) (PLGA) NPs were stabilized by coating with poly(vinyl alcohol) (PVA), and copolymer polyvinyl-pyrrolidone (PVP) was used to conjugate herceptin (antibody) with PLGA NPs for promoting the site-specific intracellular delivery of Tam against HER2 receptor overexpressed breast cancer (MCF-7) cells. The Tam-loaded PVP-PLGA NPs and herceptin-conjugated Tam-loaded PVP-PLGA NPs were characterized in terms of morphology, size, surface charge, and structural chemistry by dynamic light scattering (DLS), Transmission electron microscopy (TEM), ζ potential analysis, 1H nuclear magnetic resonance (NMR), and Fourier transform infrared (FT-IR) spectroscopy. pH-based drug release property and the anticancer activity (in vitro and in vivo models) of the herceptin conjugated polymeric NPs were evaluated by flow cytometry and confocal image analysis. Besides, the extent of cellular uptake of drug via HER2 receptor-mediated endocytosis by herceptin-conjugated Tam-loaded PVP-PLGA NPs was examined. Furthermore, the possible signaling pathway of apoptotic induction in MCF-7 cells was explored by Western blotting, and it was demonstrated that drug-loaded PLGA NPs were capable of inducing apoptosis in a caspase-dependent manner. Hence, this nanocarrier drug delivery system (DDS) not only actively targets a multidrug-resistance (MDR) associated phenotype (HER2 receptor overexpression) but also improves therapeutic efficiency by enhancing the cancer cell targeted delivery and sustained release of therapeutic agents.

[1]  Jung-Hwan Park,et al.  Dissolving microneedles for transdermal drug delivery. , 2008, Biomaterials.

[2]  Mark R Prausnitz,et al.  Fabrication of dissolving polymer microneedles for controlled drug encapsulation and delivery: Bubble and pedestal microneedle designs. , 2010, Journal of pharmaceutical sciences.

[3]  H. Yoshino,et al.  Drug release characteristics of multi-reservoir type microspheres with poly(dl-lactide-co-glycolide) and poly(dl-lactide). , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[4]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[5]  J. Laubach,et al.  Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Thangam,et al.  pH-responsive drug delivery of chitosan nanoparticles as Tamoxifen carriers for effective anti-tumor activity in breast cancer cells. , 2013, Colloids and surfaces. B, Biointerfaces.

[7]  Shu Chien,et al.  Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases , 2003 .

[8]  Ryan F. Donnelly,et al.  Design, Optimization and Characterisation of Polymeric Microneedle Arrays Prepared by a Novel Laser-Based Micromoulding Technique , 2010, Pharmaceutical Research.

[9]  Jean M. J. Fréchet,et al.  Soluble Polymer Carriers for the Treatment of Cancer: The Importance of Molecular Architecture , 2010 .

[10]  Seiji Aoyagi,et al.  Biodegradable polymer needle with various tip angles and consideration on insertion mechanism of mosquito's proboscis , 2008 .

[11]  Jung-Hwan Park,et al.  Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery , 2004, The 26th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[12]  G. Hortobagyi,et al.  Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. , 2001, The oncologist.

[13]  Jun Ding,et al.  Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers. , 2012, Biomaterials.

[14]  G. Borchard,et al.  Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic immunomodulator for mucosal immunization. , 2013, Molecular pharmaceutics.

[15]  K. Shen,et al.  Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .

[16]  J. Thigpen,et al.  Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer , 2012 .

[17]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[18]  A. Mishra,et al.  Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[19]  S. Chien,et al.  Chemotherapeutic engineering : Vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168h in vivo , 2007 .

[20]  Yueshan Huang,et al.  Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma. , 2011, Bioorganic & medicinal chemistry.

[21]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[22]  Jun Wang,et al.  Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. , 2011, ACS nano.

[23]  S. Feng,et al.  Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. , 2012, Biomaterials.

[24]  R. Duncan.  The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[25]  Hong Wu,et al.  Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')(2) for hepatocellular carcinoma. , 2010, Biomacromolecules.

[26]  V. Labhasetwar,et al.  Critical Determinants in PLGA/PLA Nanoparticle-Mediated Gene Expression , 2004, Pharmaceutical Research.

[27]  K. Blackwell,et al.  Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. , 2008, The oncologist.

[28]  Chandra Sekhar Kolli,et al.  Characterization of Solid Maltose Microneedles and their Use for Transdermal Delivery , 2007, Pharmaceutical Research.

[29]  K. Avgoustakis,et al.  Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. , 2003, International journal of pharmaceutics.

[30]  Jayanth Panyam,et al.  Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  Janko Kos,et al.  Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[32]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[33]  Mark R Prausnitz,et al.  Minimally Invasive Protein Delivery with Rapidly Dissolving Polymer Microneedles , 2008, Advanced materials.

[34]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[35]  Balu Ranganathan,et al.  Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. , 2008, Biomaterials.

[36]  J. Lehár,et al.  Synergistic drug combinations improve therapeutic selectivity , 2009, Nature Biotechnology.

[37]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[38]  Zhiping Zhang,et al.  pH-sensitive docetaxel-loaded D-α-tocopheryl polyethylene glycol succinate-poly(β-amino ester) copolymer nanoparticles for overcoming multidrug resistance. , 2013, Biomacromolecules.

[39]  B. Chung,et al.  Anticancer drug-loaded gliadin nanoparticles induce apoptosis in breast cancer cells. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[40]  Si-Shen Feng,et al.  Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. , 2005, Biomaterials.

[41]  J. Woodcock,et al.  Development of novel combination therapies. , 2011, The New England journal of medicine.

[42]  Kai Li,et al.  Herceptin functionalized polyhedral oligomeric silsesquioxane - conjugated oligomers - silica/iron oxide nanoparticles for tumor cell sorting and detection. , 2011, Biomaterials.

[43]  F. Colotta.  Anticancer drug discovery and development. , 2008, Advances in experimental medicine and biology.

[44]  Xianglong Hu,et al.  Photo-Triggered Release of Caged Camptothecin Prodrugs from Dually Responsive Shell Cross-Linked Micelles , 2013 .

[45]  Jing Zhao,et al.  Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. , 2013, Biomaterials.